Dergiler / Turkish Journal of Gastroenterology / 2017 / Cilt: 28 - Sayı: 2

Endoscopic balloon dilation for stenotic lesions in Crohn's disease

Sayfa
117–124
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

Thus, EBD is considered to be an effective alternative treatment for intestinal stenotic lesions in patients with CD.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Background/Aims: Endoscopic balloon dilation (EBD) can serve as an alternative to surgery for intestinal stenosis associated with Crohn's disease (CD).
📊
Temel Bulgular & Veri:Here we sought to determine the therapeutic efficacy and safety of EBD for intestinal stenosis in CD.Materials and Methods: Of 43 patients with CD accompanied by intestinal stenosis, 30 underwent EBD.
💡
Sonuç & Katkı:Thus, EBD is considered to be an effective alternative treatment for intestinal stenotic lesions in patients with CD.
🔬Tür:Araştırma Makalesi
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:Alan Parametreleri

Özet

Background/Aims: Endoscopic balloon dilation (EBD) can serve as an alternative to surgery for intestinal stenosis associated with Crohn's disease (CD). However, there has been controversy regarding the efficacy and safety of EBD. Here we sought to determine the therapeutic efficacy and safety of EBD for intestinal stenosis in CD.Materials and Methods: Of 43 patients with CD accompanied by intestinal stenosis, 30 underwent EBD. These 30 patients were examined retrospectively in terms of the scope passage rate, surgery-free rate, and whether or not the observation of the distal intestinal tract influenced the therapeutic strategy.Results: The overall scope passage and surgery-free rates were 90.0% and 76.7%, respectively. There were no statistically significant differences in the site of the dilated intestinal tract among groups. Patients who had inflammation in the distal intestinal tract alone after EBD accounted for 56.7%. The rate of re-dilation was 46.7%, and time until re-dilation was 6.6±3.6 months.Conclusion: EBD was associated with favorable short-term and long-term outcomes and good safety. Observation of the distal intestinal tract influenced the decision-making process for therapeutic strategies. The results of this study suggest that EBD may allow the postponement or even avoidance of surgery, enabling not only intestinal dilation but also the evaluation of mucosal healing to be performed. Thus, EBD is considered to be an effective alternative treatment for intestinal stenotic lesions in patients with CD.

🔖

Bu Makaleye Atıf Yap

KANAMORİ, A., SUGAYA, T., TOMİNAGA, K., TAKAHASHİ, F., TAKENAKA, K., HOSHİNO, A., KOİKE, T., NAKANO, M., HİRAİSHİ, H. (2017). Endoscopic balloon dilation for stenotic lesions in Crohn's disease. Turkish Journal of Gastroenterology, Cilt: 28 - Sayı: 2, 117–124. https://ajindex.com/articles/411308

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (15)

  1. Yanai H, Hanauer SB. Assessing response and loss of response to biological therapies in IBD. Am J Gastroenterol 2011
  2. [CrossRef] Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance inflix- imab for Crohn's disease: the ACCENT I randomised trial. Lancet 2002
  3. [CrossRef] Sands BE, Anderson FH, Bernstein CN, et al. Infliximab mainte- nance therapy for fistulizing Crohn's disease. New Engl J Med 2004
  4. [CrossRef] Rutgeerts P, Van Assche G, Vermeire S. Optimizing anti TNF treat- ment in inflammatory bowel disease. Gastroenterology 2004
  5. [CrossRef] Ford AC, Sandborn WJ, Khan KJ, Hanauer SB, Talley NJ, Moayyedi P. Efficacy of biological therapies in inflammatory bowel disease: systematic review and meta-analysis. Am J Gastroenterol 2011
  6. [CrossRef] Hanauer SB, Sandborn WJ, Rutgeerts P, et al. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. Gastroenterology 2006
  7. [CrossRef] Sandborn WJ, Rutgeerts P, Enns R, et al. Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial. Ann Intern Med 2007
  8. [CrossRef] Colombel JF, Sandborn WJ, Rutgeerts P, et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology 2007
  9. [CrossRef] Van Assche G, Geboes K, Rutgeerts P. Medical therapy for Crohn's disease strictures. Inflamm Bowel Dis 2004
  10. [CrossRef] Futami K, Arima S. Role of strictureplasty in surgical treatment of Crohn's disease. J Gastroenterol 2005
  11. 40 (Suppl 16): 35-9. [Cross- Ref] Dietz DW, Laureti S, Strong SA, et al. Safety and longterm efficacy of strictureplasty in 314 patients with obstructing small bowel Crohn's disease. J Am Coll Surgeons 2001
  12. [CrossRef] De Cruz P, Kamm MA, Prideaux L, Allen PB, Desmond PV. Post- operative recurrent luminal Crohn's disease: a systematic review. Inflamm Bowel Dis 2012
  13. [CrossRef] Rutgeerts P. Protagonist et al. Crohn's disease recurrence can be prevented after ileal resection. Gut 2002
  14. [CrossRef] Wibmer AG, Kroesen AJ, Gröne J, Buhr HJ, Ritz JP. Comparison of strictureplasty and endoscopic balloon dilation for stricturing Crohn's disease-review of the literature. Int J Colorectal Dis 2010
  15. [CrossRef] Yamamoto T. Factors affecting recurrence after surgery for Crohn's disease. World